Karl-Anton A. Kreuzer, MD

Consultant
University Hospital Cologne, Germany

N/A

Poster(s):

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial